Clofarabine

Catalog No.S1218 Synonyms: Clolar

For research use only.

Clofarabine (Clolar) inhibits the enzymatic activities of ribonucleotide reductase (RNR) (IC50 = 65 nM) and DNA polymerase. Clofarabine induces autophagy and apoptosis.

Clofarabine Chemical Structure

CAS No. 123318-82-1

Selleck's Clofarabine has been cited by 17 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Other DNA/RNA Synthesis Products

Biological Activity

Description Clofarabine (Clolar) inhibits the enzymatic activities of ribonucleotide reductase (RNR) (IC50 = 65 nM) and DNA polymerase. Clofarabine induces autophagy and apoptosis.
Targets
Ribonucleotide reductase [1]
(Cell-free assay)
65 nM
In vitro

Clofarabine is efficiently transported into cells via two facilitative or equilibrative nucleoside transporters, hENT1 and hENT2, and a concentrative nucleoside transporter, hCNT253. Clofarabine is phosphorylated in a stepwise manner by cytosolic kinases to the nucleotide analogues clofarabine 5′-mono-, di- and triphosphate following entry into cells, with Clofarabine triphosphate being the active form. Clofarabine 5′-mono-, di- and triphosphate are not substrates for nucleoside transporters and must be enzymatically converted by 5′-nucleotidase back to their dephosphorylated nucleoside form for transport out of the cell. Clofarabine triphosphate is a potent inhibitor of ribonucleotide reductase (IC50 = 65 nM), presumably by binding to the allosteric site on the regulatory subunit. Clofarabine has also been shown to act directly on mitochondria by altering the transmembrane potential with release of cytochrome c, apoptotic-inducing factor (AIF), apoptosis protease-activating factor 1 (APAF1) and caspase 9 into the cytosol. Clofarabine demonstrates strong in vitro growth inhibition and cytotoxic activity (IC50 values = 0.028–0.29 μM) in a wide variety of leukaemia and solid tumour cell lines. Clofarabine has been shown to increase the activity of dCK in HL60 cells, and increases the formation of the mono-, di-, and triphosphates of ara-C in K562 cells36. [1] Clofarabine (10 μM) inhibits the repair initiated by 4-hydroperoxycyclophosphamide (4-HC), with inhibition peaking at the intracellular concentrations of 5 μM in chronic lymphocytic leukemia (CLL) lymphocytes. Clofarabine (10 μM) combined with 4-hydroperoxycyclophosphamide (4-HC) produces more than additive apoptotic cell death than the sum of each alone. [2] Clofarabine (1 μM) combined with ara-C (10 μM) results in a biochemical modulation of ara-CTP and synergistic cell kill in K562 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K562 cell MUXDfZRwfG:6aXPpeJkh[XO|YYm= M1T2OmNwdXCxdX7kJJdieyC2ZYP0[YQh\m:{IHP5eI91d3irY3n0fUBi\2GrboP0JGs2PjJiY3XscEBtcW6nczygTWM2OD1yLkCwN{DPxE1? Mn\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd|MkW1Okc,OTd|MkW1Olww[T5?
HEp-2 cell M1WxUmN6fG:2b4jpZ4l1gSCjc4PhfS=> MVHDc41xd3WwZDD3ZZMhfGW|dHXkJIZweiCleYTveI95cWOrdImgZYdicW6|dDDISZAuOiClZXzsJIxqdmW|LDDJR|UxRTBwMEGyJO69VQ>? MkPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd|MkW1Okc,OTd|MkW1Olww[T5?
CCRF-CEM cell lines M1e5[mN6fG:2b4jpZ4l1gSCjc4PhfS=> MkDHR49ueG:3bnSge4F{KHSnc4Tl[EBnd3JiY4n0c5RwgGmlaYT5JIFo[Wmwc4SgR2NTTi2FRV2gZ4VtdCCuaX7ld{whUUN3ME2wMlA2KM7:TR?= Mn36QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd|MkW1Okc,OTd|MkW1Olww[T5?
L1210 cell MVjDfZRwfG:6aXPpeJkh[XO|YYm= NF7NcnREd22yb4Xu[EB4[XNidHXzeIVlKG[xcjDjfZRwfG:6aXPpeJkh[WejaX7zeEBNOTJzMDDj[YxtKGyrbnXzMEBKSzVyPUKuN{DPxE1? MmrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd|MkW1Okc,OTd|MkW1Olww[T5?
NCI-H23 NXW1U2FqS3m2b4TvfIlkcXS7IHHzd4F6 NYXUZ3o6PSCmYYnz MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ|IHPlcIx{KGGodHXyJFUh\GG7czDifUBUWkJiYYPzZZktKEeLNUC9NE4xPM7:TR?= MmC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MkmwNFQoRjF7OUK5NFA1RC:jPh?=
PC3 M2izNmN6fG:2b4jpZ4l1gSCjc4PhfS=> NH7x[mQ2KGSjeYO= MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiNTDkZZl{KGK7IGPSRkBie3OjeTygS2k2OD1yLkC2N:69VQ>? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl{OUCwOEc,OTl7MkmwNFQ9N2F-
BT549 NUnkepVnS3m2b4TvfIlkcXS7IHHzd4F6 M2H3SlUh\GG7cx?= NWW4VYdQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSlR3NEmgZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjB4Nd88US=> M1r2[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUK5NFA1Lz5zOUmyPVAxPDxxYU6=
HCT15 Mmi1R5l1d3SxeHnjbZR6KGG|c3H5 NFy0dmY2KGSjeYO= NVf1cHh1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUWgZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjF6zszN NWHnSYVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NlkxODRpPkG5PVI6ODB2PD;hQi=>
NCI-H23 NH2wenNEgXSxc4TheIlkKGG|c3H5 NXrSbopMPSCmYYnz M2\LO2N6fG:|dHH0bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ|IHPlcIx{KGGodHXyJFUh\GG7czDifUBUWkJiYYPzZZktKEeLNUC9NE4xPM7:TR?= NYPVVVlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVExPTRpPkKxO|EyODV2PD;hQi=>
MT4 M3X6V2N6fG:|dHH0bYMh[XO|YYm= Mn3TOUBl[Xm| M3TtemN6fG:|dHH0bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNWFQh[2WubIOgZYZ1\XJiNTDkZZl{KGK7IGPSRkBie3OjeTygS2k2OD1yLkC1Ne69VQ>? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
PC3 MUTDfZRwe3SjdHnjJIF{e2G7 NYfqRW5OPSCmYYnz NGrEeFZEgXSxc4TheIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wOlPPxE1? MoSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
BT549 M4PrT2N6fG:|dHH0bYMh[XO|YYm= NIHLZ5I2KGSjeYO= MXPDfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmS1OFkh[2WubIOgZYZ1\XJiNTDkZZl{KGK7IGPSRkBie3OjeTygS2k2OD1yLkC2Oe69VQ>? Ml35QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
A549 NIT2U4REgXSxc4TheIlkKGG|c3H5 NX;wbmFCPSCmYYnz MmLrR5l1d3O2YYTpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNTDkZZl{KGK7IGPSRkBie3OjeTygS2k2OD1yLkC4Ou69VQ>? MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
HCT116 MnvVR5l1d3O2YYTpZ{Bie3OjeR?= MlL1OUBl[Xm| MXrDfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6xNFbPxE1? NH\h[Vg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
DU145 Mn;1R5l1d3O2YYTpZ{Bie3OjeR?= NGHOWmk2KGSjeYO= MlrJR5l1d3O2YYTpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6xNlXPxE1? NYj0UZNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVExPTRpPkKxO|EyODV2PD;hQi=>
HCT15 MnHJR5l1d3O2YYTpZ{Bie3OjeR?= NVHyb2xvPSCmYYnz M3TIfWN6fG:|dHH0bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{Bi\nSncjC1JIRigXNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNVjPxE1? NYW1[mtiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVExPTRpPkKxO|EyODV2PD;hQi=>
Hs578 NX7TfYxKS3m2b4P0ZZRq[yCjc4PhfS=> NV;5e3dGPSCmYYnz MW\DfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIO1O|gh[2WubIOgZYZ1\XJiNTDkZZl{KGK7IGPSRkBie3OjeTygS2k2OD1zLkK0Ne69VQ>? NF7jdGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
HL60 NELjV4tEgXSxc4TheIlkKGG|c3H5 NFSyS4s1QCCqcoO= M1K3VWN6fG:|dHH0bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6x{txO M3nhZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEKwOVczLz5{M{iyNFU4OjxxYU6=
A549 MnzGR5l1d3O2YYTpZ{Bie3OjeR?= NVq5UW5qPDhiaILz MUDDfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTkQvF2= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{MEW3Nkc,OjN6MkC1O|I9N2F-
U373-MAGI MmX3SpVv[3Srb36gZZN{[Xl? NFLwZmg2OCCwTR?= NXrONndKOiCqcoO= MUXQc5RmdnSrYYTpc44hd2ZiNT3BfoEuSy2rbnT1Z4VlKGGwdHn2bZJidCCjY4Tpeol1gSCjZ3HpcpN1KF[VVj3HJJB{\XWmb4T5dIVlKEiLVj2xJG5NPC1|IHnu[oVkfGWmIHnuJIh2dWGwIGWzO|MuVUGJSTDj[YxteyCjc4Pld5Nm\CCjczC1MWF7[S2FIFXDOVAh[XRiNUCgcm0heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUA2NUG8YT3DJIFl\Gm2aX;uJIZweiB{IHjyd{BidmRic4Xid4VyfWWwdDD2bZJidCCrbn\lZ5Rqd25ibXXhd5UtKEWFNUC9N|AvPM7:TR?= M1W5XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
U373-MAGI NUi3[o83SW62aY\pdoFtKGG|c3H5 M2qwXVUxKG6P M1P2[VQhcHK| MV7BcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDWV3YuTyCyc3X1[I91gXCnZDDITXYuOSCQTEStN{Bqdm[nY4Tl[EBqdiCqdX3hckBWOzd|LV3BS2kh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwII\pdoFtKGmwZnXjeIl3cXS7IHH0JFUxKG6PIHnuZ5Vj[XSnZDDmc5IhPCCqcoOgdJJqd3JidH:geolz[WxiaX7m[YN1cW:wIH3lZZN2emWmIHH0JFczKGi{czDwc5N1KGmwZnXjeIlwdiCkeTDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXN? Mo\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI MYPGeY5kfGmxbjDhd5NigQ>? MWSyNFAhdk1? MV[2JIhzew>? NW\UW2dCWmWmdXP0bY9vKGmwIHTHWHAhdGW4ZXygbY4hcHWvYX6gWVM4Oy2PQVfJJINmdGy|IHH0JFIxOCCwTTDh[pRmeiB4IHjyd{BjgSCOQz3NV{9OWyCjbnHsfZNqew>? M3ribFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
U373-MAGI M4Plb2Z2dmO2aX;uJIF{e2G7 Mn3SNlAxKG6P MnfROkBpenN? NEL1VmtT\WS3Y4Tpc44hcW5iZFPUVEBt\X[nbDDpckBpfW2jbjDVN|c{NU2DR1mgZ4VtdHNiYYSgNlAxKG6PIHHmeIVzKDZiaILzJIJ6KEyFLV3TM21UKGGwYXz5d4l{ NIjoSWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO|I3OCd-MkexNVczPjB:L3G+
U373-MAGI M13mN2Z2dmO2aX;uJIF{e2G7 M4HWbVIxOCCwTR?= NW\PS4w1PiCqcoO= NVXhVHlxWmWmdXP0bY9vKGmwIHTBWHAhdGW4ZXygbY4hcHWvYX6gWVM4Oy2PQVfJJINmdGy|IHH0JFIxOCCwTTDh[pRmeiB4IHjyd{BjgSCOQz3NV{9OWyCjbnHsfZNqew>? NWn6N5l5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
U373-MAGI NETDd2pHfW6ldHnvckBie3OjeR?= MUm1NEBvVQ>? M3:wW|IhcHK| NX\nZlJtWmWmdXP0bY9vKGmwIHTDWHAhdGW4ZXygbY4hcHWvYX6gWVM4Oy2PQVfJJINmdGy|IHH0JFUxKG6PIIDy[Ylv[3WkYYTl[EBnd3JiMjDodpMh\m:ubH;3[YQh[nliNT3hfoEuSyCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1KGi{czDifUBNSy2PUz;NV{BidmGueYPpdy=> M4HwelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
U373-MAGI NWDsdmFPTnWwY4Tpc44h[XO|YYm= NIPUV44zODBibl2= MmjZNkBpenN? MXrS[YR2[3Srb36gbY4h\EOWUDDs[ZZmdCCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XRiMkCwJI5OKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhPS2jenGtR{Bi\GSrdHnvckBu\WG|dYLl[EBi\nSncjC0JIhzeyCkeTDMR{1OWy:PUzDhcoFtgXOrczDy[YxifGm4ZTD0c{A2NWG8YT3D MmTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI MWLGeY5kfGmxbjDhd5NigQ>? MWm1NEBvVQ>? MlrNNkBpenN? M1G2emlv[3KnYYPlJIlvKDVvYYrhMYREXFBxZFPUVEBz[XSrbzDpckBpfW2jbjDVN|c{NU2DR1mgZ4VtdHNiYYSgOVAhdk1icILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSB3LXH6ZU1lSyCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1KGi{czDifUBNSy2PUz;NV{BidmGueYPpd{Bz\WyjdHn2[UB1dyB3LXH6ZU1lSw>? NE[4dlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO|I3OCd-MkexNVczPjB:L3G+
U373-MAGI MUfGeY5kfGmxbjDhd5NigQ>? NUjBT4djOjByIH7N NHnscHgzKGi{cx?= MVfJcoNz\WG|ZTDpckA2NWG8YT3kR3RRN2SFVGCgdoF1cW9iaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG2IEKwNEBvVSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KDVvYYrhMYREKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK|IHL5JGxENU2VL13TJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKDVvYYrhMYRE MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-
U373-MAGI M2DYOGZ2dmO2aX;uJIF{e2G7 NF;NdnIzODBibl2= M{DFflIhcHK| NEW3cGhT\WS3Y4Tpc44hcW5iZGLHWU1VWCCuZY\lcEBqdiCqdX3hckBWOzd|LV3BS2kh[2WubIOgZZQhOjByIH7NJJBz\WmwY4XiZZRm\CCob4KgNkBpenNiZn;scI94\WRiYomgOU1igmFvQzDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB2IHjyd{BjgSCOQz3NV{9OWyCjbnHsfZNqew>? NFvHTmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO|I3OCd-MkexNVczPjB:L3G+
U373-MAGI NEG3VVhHfW6ldHnvckBie3OjeR?= M4rB[lIxOCCwTR?= NVTtUlR1OiCqcoO= NFv2bWNT\WS3Y4Tpc44hcW5iNT3hfoEu\EOWUDDs[ZZmdCCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XRiMkCwJI5OKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhPS2jenGtR{Bi\GSrdHnvckBu\WG|dYLl[EBi\nSncjC0JIhzeyCkeTDMR{1OWy:PUzDhcoFtgXOrcx?= NH3lNnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO|I3OCd-MkexNVczPjB:L3G+
U373-MAGI NXP3dohDTnWwY4Tpc44h[XO|YYm= NWX1T4JOOjByIH7N MkD6NkBpenN? MlHWVoVlfWO2aX;uJIlvKGSFVGCgcIV3\WxiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG2IEKwNEBvVSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KDVvYYrhMYREKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK|IHL5JGxENU2VL13TJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKDVvYYrhMYRE MlvXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI MWjGeY5kfGmxbjDhd5NigQ>? Mn;LOVAhdk1? M3fZZlIhcHK| NGLGSmJT\WS3Y4Tpc44hcW5iZFPUVEBt\X[nbDDpckBpfW2jbjDVN|c{NU2DR1mgZ4VtdHNiYYSgOVAhdk1icILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSB3LXH6ZU1lSyCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1KGi{czDifUBNSy2PUz;NV{BidmGueYPpd{Bz\WyjdHn2[UB1dyB3LXH6ZU1lSw>? NVfORlU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
TC32 M1f2RpFJXFNiYYPzZZk> NYT2Vm5JeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGTDN|Ih[2WubIO= M3HZRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY M1T5OZFJXFNiYYPzZZk> NHTnW5hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?= NU\DZoFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 MoL6dWhVWyCjc4PhfS=> NHLJfnpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> MnPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 MoPRdWhVWyCjc4PhfS=> NIrqPFdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MoHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC NFHjN3ZyUFSVIHHzd4F6 Mn2zdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= MorCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 M1jIc5FJXFNiYYPzZZk> M3z6dpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= M4LD[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 NIf4THJyUFSVIHHzd4F6 M1vCV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 M1;rfpFJXFNiYYPzZZk> NYPDcpByeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 NX2wTWY3eUiWUzDhd5NigQ>? MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| NFfC[Jc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) M3zsXZFJXFNiYYPzZZk> NYO3VZlieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz NVvL[Vk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 NUjZdYs3eUiWUzDhd5NigQ>? NGf2b2JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSjF4NEOgZ4VtdHN? MkCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 NHjRTXlyUFSVIHHzd4F6 NYfLXmdweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl? M1X5flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MWTxTHRUKGG|c3H5 NUnRc|BYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NWDPbXd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 NXfpPIJSeUiWUzDhd5NigQ>? NFTmbY9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>? MkC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 NEjScnhyUFSVIHHzd4F6 MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{ MnnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 NGOzVFZyUFSVIHHzd4F6 M1L2bJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{ M4XTWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32 NHT3bZFyUFSVIHHzd4F6 MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR|MzKGOnbHzz NFfO[|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) MkXqdWhVWyCjc4PhfS=> NUTDXJBMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? M3\XRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30 MlzqdWhVWyCjc4PhfS=> Ml6wdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=> NX;LfWtIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 NEi1VXByUFSVIHHzd4F6 MoridWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV4Fwey1{IHPlcIx{ M4OyT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 NVPnTZZoeUiWUzDhd5NigQ>? MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 M13B[JFJXFNiYYPzZZk> NVj3VZVZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| NIjXelk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) NID2SpByUFSVIHHzd4F6 NUPYWVU2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= Ml3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Granta NFGz[|FEgXSxdH;4bYNqfHliYYPzZZk> NXL5cYMzPzJiaILz M{HybWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdz[W62YTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMEG3{txO MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF5NkWzOUc,OzBzN{[1N|U9N2F-
HL60 NG[xW2VEgXSxdH;4bYNqfHliYYPzZZk> M2LrT|czKGi{cx?= M4nxcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjB2zszN MlvNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzN{[1N|UoRjNyMUe2OVM2RC:jPh?=
CCRF-CEM NH:0NGhEgXSxdH;4bYNqfHliYYPzZZk> MYS3NkBpenN? MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDR3JHNUOHTTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMES0{txO MnfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzN{[1N|UoRjNyMUe2OVM2RC:jPh?=
RL MljFR5l1d3SxeHnjbZR6KGG|c3H5 M1rKUlczKGi{cx?= MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSUEBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuN|jPxE1? NHy3fIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEG3OlU{PSd-M{CxO|Y2OzV:L3G+
In vivo Clofarabine administered intraperitoneally has significant activity against a wide variety of human tumour xenografts implanted subcutaneously in athymic nude or severe combined immune deficiency mice. [1]

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300 +1% Tween 80+ddH2O
For best results, use promptly after mixing.

8mg/mL

Chemical Information

Molecular Weight 303.68
Formula

C10H11ClFN5O3

CAS No. 123318-82-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03609814 Completed Drug: Clofarabine|Drug: Fludarabine Injection Hematologic Malignancies|Nonmalignant Diseases|Immunodeficiencies|Hemoglobinopathies|Genetic Inborn Errors of Metabolism|Fanconi''s Anemia|Thalassemia|Sickle Cell Disease University of California San Francisco January 26 2016 --
NCT02425904 Active not recruiting Drug: Clofarabine Langerhans Cell Histiocytosis Dana-Farber Cancer Institute|Sanofi|St. Baldrick''s Foundation|Cookies for Kids'' Cancer|North American Consortium for Histiocytosis May 2015 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Clofarabine | Clofarabine supplier | purchase Clofarabine | Clofarabine cost | Clofarabine manufacturer | order Clofarabine | Clofarabine distributor